vs
Lakeside Holding Ltd（LSH）与Vivos Therapeutics, Inc.（VVOS）财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是Vivos Therapeutics, Inc.的1.8倍（$7.0M vs $3.8M），Lakeside Holding Ltd净利率更高（-22.6% vs -180.3%，领先157.7%），Lakeside Holding Ltd同比增速更快（95.0% vs 3.4%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
Beam Therapeutics是一家总部位于美国马萨诸塞州剑桥市的美国生物技术企业，专注于基因疗法与基因编辑领域的研发工作。公司依托CRISPR碱基编辑和引导编辑技术开发疗法，可在不产生DNA双链断裂的情况下，对DNA序列中的单个核苷酸进行酶修饰。
LSH vs VVOS — 直观对比
营收规模更大
LSH
是对方的1.8倍
$3.8M
营收增速更快
LSH
高出91.6%
3.4%
净利率更高
LSH
高出157.7%
-180.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $3.8M |
| 净利润 | $-1.6M | $-6.9M |
| 毛利率 | 27.2% | 78.1% |
| 营业利润率 | -21.3% | -166.8% |
| 净利率 | -22.6% | -180.3% |
| 营收同比 | 95.0% | 3.4% |
| 净利润同比 | 18.7% | -143.8% |
| 每股收益（稀释后） | $-0.08 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHVVOS
| Q4 25 | $7.0M | $3.8M | ||
| Q3 25 | $6.1M | $6.8M | ||
| Q2 25 | $6.3M | $3.8M | ||
| Q1 25 | $3.8M | $3.0M | ||
| Q4 24 | $3.6M | $3.7M | ||
| Q3 24 | $4.1M | $3.9M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | — | $3.4M |
净利润LSHVVOS
| Q4 25 | $-1.6M | $-6.9M | ||
| Q3 25 | $-1.4M | $-5.4M | ||
| Q2 25 | $-893.1K | $-5.0M | ||
| Q1 25 | $-1.1M | $-3.9M | ||
| Q4 24 | $-1.9M | $-2.8M | ||
| Q3 24 | $-1.3M | $-2.6M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-3.8M |
毛利率LSHVVOS
| Q4 25 | 27.2% | 78.1% | ||
| Q3 25 | 18.2% | 58.0% | ||
| Q2 25 | 26.7% | 55.2% | ||
| Q1 25 | 18.8% | 50.0% | ||
| Q4 24 | -1.2% | 56.7% | ||
| Q3 24 | 12.8% | 60.5% | ||
| Q2 24 | — | 65.4% | ||
| Q1 24 | — | 56.7% |
营业利润率LSHVVOS
| Q4 25 | -21.3% | -166.8% | ||
| Q3 25 | -20.8% | -69.8% | ||
| Q2 25 | -8.9% | -127.4% | ||
| Q1 25 | -28.2% | -129.9% | ||
| Q4 24 | -55.6% | -75.9% | ||
| Q3 24 | -32.5% | -68.5% | ||
| Q2 24 | — | -47.8% | ||
| Q1 24 | — | -110.7% |
净利率LSHVVOS
| Q4 25 | -22.6% | -180.3% | ||
| Q3 25 | -22.2% | -79.6% | ||
| Q2 25 | -14.2% | -131.2% | ||
| Q1 25 | -28.2% | -128.1% | ||
| Q4 24 | -54.1% | -76.4% | ||
| Q3 24 | -32.7% | -67.8% | ||
| Q2 24 | — | -47.6% | ||
| Q1 24 | — | -110.1% |
每股收益（稀释后）LSHVVOS
| Q4 25 | $-0.08 | $-0.58 | ||
| Q3 25 | $-0.09 | $-0.49 | ||
| Q2 25 | $-0.11 | $-0.55 | ||
| Q1 25 | $-0.14 | $-0.45 | ||
| Q4 24 | $-0.26 | $0.41 | ||
| Q3 24 | $-0.18 | $-0.40 | ||
| Q2 24 | — | $-0.60 | ||
| Q1 24 | — | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $2.0M |
| 总债务越低越好 | $2.4M | $2.9M |
| 股东权益账面价值 | $12.2M | $-1.5M |
| 总资产 | $24.3M | $25.2M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LSHVVOS
| Q4 25 | $1.6M | $2.0M | ||
| Q3 25 | $4.5M | $3.1M | ||
| Q2 25 | $5.0M | $4.4M | ||
| Q1 25 | $1.5M | $2.3M | ||
| Q4 24 | $1.1M | $6.3M | ||
| Q3 24 | $2.7M | $6.3M | ||
| Q2 24 | — | $6.9M | ||
| Q1 24 | — | $2.6M |
总债务LSHVVOS
| Q4 25 | $2.4M | $2.9M | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | $1.2M | ||
| Q3 24 | $589.9K | $1.2M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | — |
股东权益LSHVVOS
| Q4 25 | $12.2M | $-1.5M | ||
| Q3 25 | $7.0M | $2.5M | ||
| Q2 25 | $2.8M | $4.6M | ||
| Q1 25 | $749.8K | $4.4M | ||
| Q4 24 | $1.6M | $8.0M | ||
| Q3 24 | $3.6M | $7.7M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $582.0K |
总资产LSHVVOS
| Q4 25 | $24.3M | $25.2M | ||
| Q3 25 | $18.6M | $25.6M | ||
| Q2 25 | $14.4M | $26.0M | ||
| Q1 25 | $9.9M | $11.3M | ||
| Q4 24 | $9.8M | $15.3M | ||
| Q3 24 | $10.8M | $15.3M | ||
| Q2 24 | — | $15.8M | ||
| Q1 24 | — | $11.8M |
负债/权益比LSHVVOS
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | 0.15× | ||
| Q3 24 | 0.16× | 0.16× | ||
| Q2 24 | — | 0.19× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-3.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.3M |
| 自由现金流率自由现金流/营收 | — | -139.7% |
| 资本支出强度资本支出/营收 | — | 40.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-17.8M |
8季度趋势，按日历期对齐
经营现金流LSHVVOS
| Q4 25 | $-453.5K | $-3.8M | ||
| Q3 25 | $-4.0M | $-4.2M | ||
| Q2 25 | $-483.7K | $-3.5M | ||
| Q1 25 | $-238.3K | $-3.8M | ||
| Q4 24 | $-530.2K | $-2.9M | ||
| Q3 24 | $-1.4M | $-4.2M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $-2.5M |
自由现金流LSHVVOS
| Q4 25 | — | $-5.3M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-497.4K | $-4.3M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | $-560.5K | $-3.1M | ||
| Q3 24 | $-1.4M | $-4.4M | ||
| Q2 24 | — | $-3.1M | ||
| Q1 24 | — | $-2.7M |
自由现金流率LSHVVOS
| Q4 25 | — | -139.7% | ||
| Q3 25 | — | -62.6% | ||
| Q2 25 | -7.9% | -111.6% | ||
| Q1 25 | — | -129.9% | ||
| Q4 24 | -15.6% | -84.0% | ||
| Q3 24 | -34.5% | -113.4% | ||
| Q2 24 | — | -76.7% | ||
| Q1 24 | — | -78.0% |
资本支出强度LSHVVOS
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 0.2% | 20.2% | ||
| Q1 25 | 0.0% | 4.0% | ||
| Q4 24 | 0.8% | 4.5% | ||
| Q3 24 | 0.1% | 5.0% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 4.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
VVOS
| Services | $3.2M | 84% |
| Products | $594.0K | 16% |
